Embedded Files
A New Phase in Drug Resistance
A New Phase in Drug Resistance
Jul 4, 2026
Drug resistance is a serious problem that limits the utility of existing therapeutics, causing disease relapses in patients. Scientists have studied this phenomenon for decades, with the goal of understanding and mitigating the resistance mechanisms. Drug resistance can arise through mechanisms that act:
directly on the drug (e.g., inactivation or reduced accumulation into the target cell)
directly on the target (e.g., acquisition of mutations that weaken drug binding)
through systemic adaptations (e.g., rewiring of signaling pathways, activation of back-up or redundant mechanisms and cellular players)
One form of systemic adaptations involves mechanisms mediated by biomolecular #condensates – a hot research topic these days, and a testament of its importance. Just last month, 4 original articles covered this topic, showing evidence of condensate involvement in acquired drug resistance in lung, brain, liver and bladder cancer.
What were the key findings?
Lenvatinib, a first-line treatment for unresectable hepatocellular carcinoma (a type of liver cancer), can lose its efficacy though a mechanism mediated by a drug-enhanced formation of a condensate concentrating the stress-induced chaperone, HSPA6. This systemic rearrangement of the biological processes results in suppression of a cell-death mechanism, called ferroptosis, that Lenvatinib normally activates to trigger selectively target cancer cell death.
🔗Link to the full study: https://pubmed.ncbi.nlm.nih.gov/42314062/
Temozolomide, the first-line treatment for the aggressive form of brain cancer, glioblastoma, can acquire resistance through formation of nuclear condensates enriched in the DNA damage protein BARD1. These condensates recruit molecules that reverse the drug-induced damage that leads to cancer cell death.
🔗Link to the full study: https://pubmed.ncbi.nlm.nih.gov/42309254/
Gefitinib and osimertinib – oral targeted therapies for a type of genetically-defined lung cancer that work through a similar mechanism of action, also acquire drug resistance through a condensate-mediated route. Resistant cells enhance the formation of p62/SQSTM1 condensates involved in cellular cleanup.
🔗Link to the full study: https://pubmed.ncbi.nlm.nih.gov/42360721/
Vemurafenib is a targeted therapeutic that selectively turns off abnormal growth signals in cancers driven by mutants of the BRAF gene. A proteomic study in dogs that suffer from a type of aggressive bladder cancer, showed that vemurafenib-resistant canine patients presented with systemic changes in protein expression around Cajal bodies, a condensate responsible for organizing the RNA-processing machinery.
🔗Link to the full study: https://pubmed.ncbi.nlm.nih.gov/42359562/
The common denominator in these examples is an adaptation of the cancer cell, that perceives the drug treatment as a form of stress. These adaptations lead to rewiring of the cell’s biochemical processes integrated in condensates, to counteract the drug’s action of suppressing the proliferation of cancer cells.
How are these findings relevant to solving the real life drug resistance challenges?
These drug resistance-dependent condensates are easily detectable using well-established, inexpensive and high-throughput microscopy techniques, and can be used as biomarkers
Tracking condensate biomarkers during treatment can predict drug resistance
Tracking condensate biomarkers during the drug development process could help mitigate resistance
By identifying actionable intervention points (e.g., dissolution of the condensate that facilitates resistance), physicians could prescribe combination or adjuvant treatment to restore efficacy of standard-of-care therapies.
A Hidden Vulnerability in Livestock Foot-and-Mouth Virus
A Hidden Vulnerability in Livestock Foot-and-Mouth Virus
Jun 18, 2026
Could biomolecular condensates hold the key to defeating one of Beth and Rip’s most elusive enemies? Beth and Rip of Dutton Ranch are no strangers to facing their enemies head on, with grit, determination and -- let’s admit it, sometimes🦇💩🤪 solutions, most often coming out victorious. One enemy they never saw coming left these relentless survivors completely helpless: the foot-and-mouth disease virus (FMDV).
Foot-and-mouth is a highly infectious disease with no cure, nor treatment, caused by a virus that affects cloven-hooved animals, such as cattle. FMDV outbreaks take a devastating toll on farmers’ livelihood in real life. The lack of therapeutic options is largely due to our lack of understanding of how the virus infects and hijacks the host cell's defences.
A new study from Nicolas Locker’s group at The Pirbright Institute in UK, published in the PLOS Pathogens journal, unlocks an intriguing molecular mechanism used by the virus to evade the host’s defenses and highlights a potential point for therapeutic intervention.
FMDV-infected cells do their job: (1) they sense the virus and sound the alarm that something is wrong, by inducing stress granules (SG) – a type of cytoplasmic biomolecular condensate that put a break on protein production until the stress is resolved, to preserve energy and avoid pathological aggregation of proteins and RNA; (2) activate innate immune response programs (IIR).
The virus, however, works on multiple levels to disrupt several stress and immune response mechanisms. Using an elegant experimental design, the authors demonstrate, for the first time, that the SG-mediated stress sensing and innate immune response self-defense mechanisms are uncoupled. This means that blocking the stress response does not prevent the cell from defending itself from infection through IIR.
Since the virus uses the host cell’s protein production machinery to produce its own components, it evolved a mechanism by which it reverses the SG induction to rescue protein production. It does so by cleaving a protein called G3BP1, which acts as a scaffold for SG formation.
This finding led the authors to hypothesize that SG may be an actionable point of intervention to rescue the host cell’s defenses. Treating the infected cells with a drug that prevents SG dissolution, caused delayed viral replication.
Why is this relevant? While the path from basic discovery to approved therapy takes years, these findings highlight a potential point of intervention that could be leveraged to develop antivirals that inhibit FMDV infection.
What does it mean for farmers? If an effective therapeutic were available, outbreak management would likely shift from pure containment toward more treatment-and-recovery strategies, a key to saving countless animals’ lives and the livelihood of farmers like Beth and Rip.
🔗 Link to the full article: https://pubmed.ncbi.nlm.nih.gov/42275447/
Let's connect
Let's connect
© 2026 DeMix Solutions, LLC. All rights reserved.
Page updated
Google Sites
Report abuse